Safety of Fondaparinux as Post Partum Thromboprophylaxis
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Venous thromboembolism (VTE) remains as one of leading causes of maternal morbidity and
mortality, with postpartum period carries the greatest risk. Perinatal thromboprophylaxis is
often administered based on risk-factor assessment. Low molecular weight heparin has a proven
safety profile in obstetrics population, however its porcine derived content may lead to
reduced uptake amongst certain religious groups. The investigators aimed to evaluate the
safety of fondaparinux as an alternative postpartum thromboprophylaxis.
The investigators planned a prospective, single arm, open label study. Women who fulfilled
the criteria for post natal thromboprophylaxis based on the 2015 RCOG guidelines were
recruited. Each patient would receive subcutaneous injection of Fondaparinux, 2.5mg daily for
10 days. The investigators would conduct a telephone interview on day 10 post delivery and
six week outpatient review in clinic.